|
Market Closed -
OTC Markets
23:18:24 10/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.0232 USD | -7.40% |
|
-7.20% | -10.77% |
| 05-19 | Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 11-17 | Adaptimmune Therapeutics plc Announces CEO Changes | CI |
| Market Cap | 6.14M 5.29M 4.99M 4.54M 8.49M 586M 8.57M 59.42M 22.86M 298M 23.04M 22.53M 949M | P/E 2024 |
-1.8x | P/E 2025 | 0.33x |
|---|---|---|---|---|---|
| Enterprise Value | -5.73M -4.94M -4.66M -4.24M -7.93M -547M -8.01M -55.52M -21.36M -278M -21.53M -21.06M -886M | EV / Sales 2024 |
0.34x | EV / Sales 2025 | -0.84x |
| Free-Float |
14.03% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -7.40% | ||
| 1 week | -7.20% | ||
| Current month | +3.11% | ||
| 1 month | -22.67% | ||
| 3 months | -29.48% | ||
| 6 months | +132.00% | ||
| Current year | -10.77% |
| 1 week | 0.02 |  | 0.03 |
| 1 month | 0 | | 0.03 |
| Current year | 0 | | 0.05 |
| 1 year | 0 | | 0.28 |
| 3 years | 0 | | 2.05 |
| 5 years | 0 | | 6.84 |
| 10 years | 0 | | 14.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christopher Hill
CEO | Chief Executive Officer | 46 | 14/11/2025 |
Juli P. Miller
IRC | Investor Relations Contact | - | 01/08/2016 |
Phil Bassett
PRN | Corporate Officer/Principal | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Lawrence Alleva
CHM | Chairman | 76 | 14/11/2025 |
Garry Menzel
BRD | Director/Board Member | 61 | 01/06/2023 |
Christopher Hill
BRD | Director/Board Member | 46 | 14/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 02/09/25 | Sell | Chief Financial Officer | 96,000 | 0.0060% | ||
| 28/08/25 | Sell | Compliance Officer | 207,000 | 0.0130% | ||
| 15/08/25 | NEA Management Co. LLC
| Sell | Company | 19,500,000 | 7.3571% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.40% | -7.20% | -52.85% | -96.84% | 6.63M | |
| -1.78% | -6.90% | +42.54% | -4.51% | 80.65B | |
| -1.00% | -2.50% | -19.26% | -37.42% | 59.12B | |
| +0.74% | -9.41% | +458.32% | +26.92% | 54.14B | |
| -2.00% | -5.20% | -11.09% | +27.83% | 50.1B | |
| -1.42% | -8.53% | -3.54% | +144.43% | 45.33B | |
| +2.23% | -3.25% | +50.02% | -16.82% | 31.14B | |
| -2.17% | -4.31% | +44.02% | +92.69% | 25.54B | |
| -3.92% | -7.32% | -6.49% | +166.90% | 21.8B | |
| -0.99% | -3.56% | +58.64% | +102.21% | 16.06B | |
| Average | -1.94% | -3.41% | +56.03% | +40.54% | 38.39B | |
| Weighted average by Cap. | -1.32% | -3.84% | +77.81% | +36.33% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 178M 153M 145M 132M 246M 16.99B 249M 1.72B 663M 8.65B 669M 654M 27.53B | 5.92M 5.1M 4.82M 4.39M 8.19M 565M 8.27M 57.37M 22.07M 288M 22.24M 21.76M 916M |
| Net income | -70.81M -61M -57.6M -52.42M -97.96M -6.76B -98.9M -686M -264M -3.44B -266M -260M -10.95B | 25.21M 21.71M 20.5M 18.66M 34.87M 2.41B 35.2M 244M 93.89M 1.22B 94.65M 92.57M 3.9B |
| Net Debt | -77.4M -66.67M -62.95M -57.29M -107M -7.39B -108M -750M -288M -3.76B -291M -284M -11.97B | -11.87M -10.22M -9.65M -8.79M -16.42M -1.13B -16.58M -115M -44.21M -576M -44.57M -43.59M -1.84B |
Employees
272
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/09/26 | $0.0232 | -7.40% | 63,245 |
| 09/09/26 | $0.0250 | -3.85% | 222,681 |
| 08/09/26 | $0.0260 | -2.99% | 68,147 |
| 04/09/26 | $0.0268 | +3.08% | 92,660 |
| 03/09/26 | $0.0260 | +4.00% | 82,887 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ADAPY Stock
Select your edition
All financial news and data tailored to specific country editions
